Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) drives innovation in life sciences, diagnostics, and industrial technologies through cutting-edge scientific instruments and operational excellence. This page serves as a centralized hub for all official company announcements, press releases, and market-moving developments.
Investors and industry professionals will find timely updates on earnings reports, strategic acquisitions, and product innovations that shape Danaher's leadership across healthcare and industrial markets. Our curated news collection simplifies tracking regulatory filings, partnership announcements, and operational milestones.
Key content categories include quarterly financial results, R&D breakthroughs in diagnostic systems, and updates from Danaher's core segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Bookmark this page to stay informed about developments impacting the company's position in precision medicine and industrial automation.
Danaher (NYSE: DHR) announced the appointment of Julie Sawyer Montgomery as Executive Vice President for Diagnostics, effective July 1, 2024. She succeeds Joakim Weidemanis, who will retire on September 30, 2024, after a 13-year tenure. Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, has been with Danaher since 2017 and has previously held significant roles at Beckman Coulter Diagnostics, Hospira Infusion Systems, Boston Scientific, and Boston Consulting Group. Rainer Blair, Danaher's President and CEO, commended Montgomery's leadership and commitment to innovation, customer support, and team building. Blair also acknowledged Weidemanis' strategic contributions to the company's growth and development.
Danaher (NYSE: DHR) has announced the creation of a new role, Chief Data & Artificial Intelligence (AI) Officer, appointing Dr. Martin Stumpe to the position. Dr. Stumpe previously served as Chief of AI at Tempus and has a background in AI-driven initiatives, including founding the Cancer Pathology project at Google. This move underscores Danaher's increased focus on AI to drive innovation and productivity. Additionally, Danaher will host its third annual Innovation Summit in December, which will center around AI's role in biopharmaceutical research and development.
Danaher (NYSE: DHR) has launched a collaboration with Johns Hopkins University to develop new methods for diagnosing mild Traumatic Brain Injury (TBI) using blood-based biomarkers. The partnership aims to improve the detection of specific biomarkers found in blood when brain cells are damaged, potentially leading to earlier and more precise diagnosis of TBI and improved treatment outcomes. The research, led by experts from Johns Hopkins School of Nursing and Johns Hopkins Medicine, leverages technology from Beckman Coulter Diagnostics, a Danaher subsidiary.
Danaher will have its President and CEO present at the Bank of America Securities Healthcare Conference in Las Vegas on May 14, 2024. The event will be webcasted on the company's website.
Danaher (NYSE: DHR) declared a regular quarterly cash dividend of $0.27 per share for its common stock. The dividend will be paid on July 26, 2024, to shareholders of record on June 28, 2024.
Curiox Biosystems and Beckman Coulter Life Sciences have announced a partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry, combining C-FREE™ technology with DURA Innovations. The collaboration aims to address challenges in standardization, automation, and reproducibility, paving the way for advancements in research and healthcare.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
